茅島 敦人 ( カヤシマ アツト )

Kayashima, Atsuto

写真a

所属(所属キャンパス)

医学部 内科学教室(消化器) ( 信濃町 )

職名

助教(有期)

外部リンク

 

研究分野 【 表示 / 非表示 】

  • ライフサイエンス / 消化器内科学

研究キーワード 【 表示 / 非表示 】

  • ERCP

  • ERCP後膵炎

  • 原発性硬化性胆管炎

  • 急性膵炎

  • 細菌叢

全件表示 >>

 

論文 【 表示 / 非表示 】

  • Type 1 Autoimmune Pancreatitis

    New England Journal of Medicine 2026年08月

    査読有り

  • Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease

    Okada H., Sugimoto S., Kayashima A., Mikami Y., Kanai T., Nakamoto N., Ueno M., Tabuchi T., Suzuki S., Kaieda Y., Mizushima I., Sunaga S., Usui S., Ojiro K., Taniki N., Kasuga R., Nakadai Y., Kiyohara H., Yoshimatsu Y.

    Journal of Gastroenterology 61 ( 7 ) 863 - 879 2026年07月

    査読有り,  ISSN  09441174

     概要を見る

    Primary sclerosing cholangitis (PSC) is frequently accompanied by colitis with clinicopathologic features that differ from conventional inflammatory bowel disease (IBD). Accumulating evidence indicates that PSC-associated IBD (PSC-IBD) often presents as extensive colitis with a right-sided predominant distribution and characteristic endoscopic features, such as rectal sparing and backwash ileitis. Beyond endoscopic appearance, PSC-IBD also appears to have distinct biological underpinnings, including shared genetic susceptibility, dysregulated bile acid signaling, altered gut microbial communities, and immune crosstalk along the gut–liver axis. These mechanisms may contribute not only to intestinal inflammation but also to PSC-related clinical outcomes. From a long-term perspective, patients with PSC and colitis are consistently classified as a high-risk group for colorectal neoplasia, warranting early and intensive colonoscopic surveillance. In parallel, surveillance for hepatobiliary malignancies remains central in PSC care, although risk stratification continues to evolve. Therapeutic management generally follows established IBD algorithms, yet the extent to which colitis-directed therapies modify PSC outcomes remains uncertain, with heterogeneous findings across cohorts and endpoints. In this review, we summarize current knowledge on the clinical phenotype, mechanistic framework, and outcome-driven management of PSC-IBD, and highlight future directions toward precision surveillance and mechanism-based interventions targeting bile acid–microbiota–immune interactions.

  • Clinical outcomes of endoscopic papillectomy for ampullary adenoma and adenocarcinoma: a multicenter retrospective study in Japan

    Iwasaki E., Kawashima H., Takada Y., Hara K., Iwai T., Okano N., Kubota K., Yamao T., Yamamoto K., Shiomi H., Ikezawa K., Ushio J., Kato H., Fujimori N., Katanuma A., Ozawa E., Takahara N., Nakahara K., Ueki T., Hashimoto S., Ryozawa S., Isayama H., Irisawa A., Inui K., Fujita N., Kayashima A., Horibe M., Bazerbachi F., Itoi T., Okuno N., Hasegawa R., Igarashi Y., Abe S., Takada R., Yokoyama K., Fujii Y., Matsumoto K., Ishii T., Komatsu N., Nakai Y., Nagayama R., Hinokuchi M., Tanisaka Y., Fujisawa T., Hoshi K.

    Gastrointestinal Endoscopy 103 ( 5 ) 1016 - 1027.e5 2026年05月

    査読有り,  ISSN  00165107

     概要を見る

    Background and Aims Endoscopic papillectomy (EP) is a minimally invasive treatment for ampullary epithelial tumors. However, clinical outcomes and predictors of recurrence remain unclear. Methods We conducted a multicenter, retrospective cohort study at 22 tertiary centers in Japan, including patients who underwent EP between January 2009 and December 2020. The primary outcome was cumulative recurrence in patients with histologically confirmed adenoma or adenocarcinoma. Recurrence predictors were evaluated using Cox proportional hazards model. Results Of 875 patients, 798 had confirmed ampullary epithelial tumor, and 776 were included in the long-term outcome analysis. The 3-year cumulative recurrence rate was 20%. Indeterminate (Rx) and positive (R1) resection margins were independently associated with higher recurrence compared with negative margins (R0), with hazard ratios of 2.30 (95% CI, 1.44-3.68) and 2.95 (95% CI, 1.85-4.71), respectively. R0 resection was achieved in 52.1% (416/798) of patients, with a 3-year cumulative recurrence rate of 11% (95% CI, 7.6%-15%). Conclusions Recurrence after EP for ampullary epithelial tumors is common, even after R0 resection. These findings highlight the need for long-term surveillance following EP.

  • ENDOSCOPIC SUBMUCOSAL DISSECTION INCLUDING PAPILLA (ESDIP) FOR AMPULLARY TUMORS: SHORT-AND LONG-TERM OUTCOMES AND PREDICTORS OF BILE-/PANCREATIC-DUCTAL MARGIN POSITIVITY AND LOCAL RECURRENCE

    Akimoto, T; Yahagi, N; Takatori, Y; Sasaki, M; Kubo, Y; Katsumi, A; Mizobe, R; Ishizawa, M; Murata, S; Imura, Y; Hayakawa, T; Miyazaki, K; Kayashima, A; Masunaga, T; Kirita, K; Mizutani, M; Tamagawa, H; Kawasaki, S; Horibe, M; Fukuhara, S; Tomida, H; Matsuura, N; Sujino, T; Nakayama, A; Takabayashi, K; Ito, Y; Iwasaki, E; Kato, M

    GASTROENTEROLOGY 170 ( 6 ) s581 - s581 2026年05月

    査読有り,  ISSN  0016-5085

全件表示 >>

総説・解説等 【 表示 / 非表示 】

  • Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease(タイトル和訳中)

    Okada Haruka, Sugimoto Shinya, Kayashima Atsuto, Mikami Yohei, Kanai Takanori, Nakamoto Nobuhiro

    Journal of Gastroenterology (シュプリンガー・ジャパン(株))  61 ( 7 ) 863 - 879 2026年07月

    ISSN  0944-1174

  • 腸内細菌叢と消化器疾患の病態連関 原発性硬化性胆管炎合併大腸炎における右側優位の表現型 潰瘍性大腸炎との比較検討

    岡田 はるか, 杉本 真也, 中本 伸宏, 茅島 敦人, 吉松 裕介, 谷木 信仁, 尾城 啓輔, 碓井 真吾, 三上 洋平, 金井 隆典

    日本消化器病学会雑誌 ((一財)日本消化器病学会)  123 ( 臨増総会 ) A90 - A90 2026年03月

    ISSN  0446-6586

  • 本邦におけるPPI/P-CABの服薬率と消化性潰瘍治療薬の処方動向

    茅島 敦人, 福原 誠一郎, 青木 康浩, 脇坂 悠介, 松永 崇宏, 渡邉 多代

    日本消化器病学会雑誌 ((一財)日本消化器病学会)  122 ( 臨増大会 ) A685 - A685 2025年10月

    ISSN  0446-6586

  • Klebsiella pneumoniaeに起因した肝膿瘍におけるstring testの臨床的意義

    岡村 真伊, 福原 誠一郎, 黒崎 颯, 先崎 光, 鈴木 徹志郎, 吉村 梨沙, 花岡 孝行, 山本 晴二郎, 荒金 直美, 東條 誠也, 青木 康浩, 茅島 敦人, 脇坂 悠介, 松永 崇宏, 渡邉 多代

    日本消化器病学会雑誌 ((一財)日本消化器病学会)  122 ( 臨増大会 ) A726 - A726 2025年10月

    ISSN  0446-6586

  • 膵神経内分泌腫瘍における超音波内視鏡微小血流イメージング技術の有用性

    早川 宇宙, 岩崎 栄典, 佐藤 翼, 岡田 はるか, 中島 悠貴, 茅島 敦人, 清野 隆史, 川崎 慎太郎, 堀部 昌靖, 北郷 実, 金井 隆典

    日本消化器病学会雑誌 ((一財)日本消化器病学会)  122 ( 臨増総会 ) A318 - A318 2025年03月

    ISSN  0446-6586

全件表示 >>